Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of $10.64 million. The enterprise value is -$16.58 million.
Important Dates
The last earnings date was Thursday, March 27, 2025, after market close.
| Earnings Date | Mar 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 33.57 million shares outstanding. The number of shares has increased by 3.37% in one year.
| Current Share Class | 31.93M |
| Shares Outstanding | 33.57M |
| Shares Change (YoY) | +3.37% |
| Shares Change (QoQ) | +1.25% |
| Owned by Insiders (%) | 6.60% |
| Owned by Institutions (%) | 17.21% |
| Float | 29.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.40 |
| Forward PS | 6.75 |
| PB Ratio | 0.19 |
| P/TBV Ratio | 0.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.41, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.41 |
| Quick Ratio | 4.08 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -53.65% and return on invested capital (ROIC) is -34.44%.
| Return on Equity (ROE) | -53.65% |
| Return on Assets (ROA) | -31.45% |
| Return on Invested Capital (ROIC) | -34.44% |
| Return on Capital Employed (ROCE) | -70.71% |
| Revenue Per Employee | $25,259 |
| Profits Per Employee | -$242,832 |
| Employee Count | 155 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.73 |
Taxes
In the past 12 months, Co-Diagnostics has paid $57,368 in taxes.
| Income Tax | 57,368 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.05% in the last 52 weeks. The beta is 1.30, so Co-Diagnostics's price volatility has been higher than the market average.
| Beta (5Y) | 1.30 |
| 52-Week Price Change | -72.05% |
| 50-Day Moving Average | 0.59 |
| 200-Day Moving Average | 1.02 |
| Relative Strength Index (RSI) | 22.49 |
| Average Volume (20 Days) | 265,483 |
Short Selling Information
The latest short interest is 202,412, so 0.60% of the outstanding shares have been sold short.
| Short Interest | 202,412 |
| Short Previous Month | 193,713 |
| Short % of Shares Out | 0.60% |
| Short % of Float | 0.68% |
| Short Ratio (days to cover) | 0.97 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of $3.92 million and -$37.64 million in losses. Loss per share was -$1.24.
| Revenue | 3.92M |
| Gross Profit | 2.92M |
| Operating Income | -40.08M |
| Pretax Income | -35.81M |
| Net Income | -37.64M |
| EBITDA | -38.70M |
| EBIT | -40.08M |
| Loss Per Share | -$1.24 |
Full Income StatementBalance Sheet
The company has $29.75 million in cash and $2.15 million in debt, giving a net cash position of $27.60 million or $0.82 per share.
| Cash & Cash Equivalents | 29.75M |
| Total Debt | 2.15M |
| Net Cash | 27.60M |
| Net Cash Per Share | $0.82 |
| Equity (Book Value) | 54.31M |
| Book Value Per Share | 1.64 |
| Working Capital | 24.98M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.16 million and capital expenditures -$748,352, giving a free cash flow of -$29.90 million.
| Operating Cash Flow | -29.16M |
| Capital Expenditures | -748,352 |
| Free Cash Flow | -29.90M |
| FCF Per Share | -$0.89 |
Full Cash Flow StatementMargins
| Gross Margin | 74.48% |
| Operating Margin | -1,023.75% |
| Pretax Margin | -959.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |